SCHEMBL6412554

SCHEMBL6412554

CN(Cc1ccc(F)c(Cl)c1)C(=O)C=C(O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PIK3CA P42336 1/20 0.39
RAB9A P51151 2/20 0.38
HTT P42858 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
AOC3 Q16853 1/20 0.38
ERCC1 P07992 1/20 0.38
ERCC4 Q92889 1/20 0.38
RPA1 P27694 1/20 0.37
SLC6A9 P48067 2/20 0.36
KCNH2 Q12809 2/20 0.36
CNR2 P34972 1/20 0.36
GRM2 Q14416 1/20 0.36
GRM3 Q14832 1/20 0.36
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412551 1.00 USP30 (0.39) USP30ALDH1A1KDM4EL3MBTL1PIK3CA
SCHEMBL6418668 0.90 USP30 (0.39) USP30ALDH1A1RAB9AHTTAOC3
SCHEMBL6418663 0.90 USP30 (0.39) USP30ALDH1A1RAB9AHTTAOC3
SCHEMBL6417149 0.88 RIPK1 (0.44) ALDH1A1KDM4ERAB9AHTTMAOA
SCHEMBL6417152 0.88 RIPK1 (0.44) ALDH1A1KDM4ERAB9AHTTMAOA
SCHEMBL6413065 0.85 MMP13 (0.38) ALDH1A1MAOAMAOBAOC3GRM2
SCHEMBL6413062 0.85 MMP13 (0.38) ALDH1A1MAOAMAOBAOC3GRM2
SCHEMBL6412044 0.84 CYP1A2 (0.44) ALDH1A1KDM4EHTTMAOAMAOB
SCHEMBL6412037 0.84 CYP1A2 (0.44) ALDH1A1KDM4EHTTMAOAMAOB
SCHEMBL6877310 0.84 RPA1 (0.38) ALDH1A1KDM4EL3MBTL1PIK3CARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 USP30 4433/4885ALDH1A1 1020/4885KDM4E 1795/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 USP30 4348/4885ALDH1A1 239/4885KDM4E 847/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 USP30 4348/4885ALDH1A1 239/4885KDM4E 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.